However, in prostate cancer cells, Glo2 takes on an antiapoptotic nonenzymatic role, stimulating cell proliferation and eluding apoptosis through mechanisms dependent on the androgen receptor and involving the p53-p21 axis [61]. This evidence concerns the gene HAGH and prostate carcinoma.